Reference | No. of patients | Male, % | Mean age, year | Intervention | Outcomes | Study design | Follow up | ||
---|---|---|---|---|---|---|---|---|---|
CLIA | C | CLIA | C | ||||||
Nechleba 2005 [15] | 14 | 16 | 63.3 | 65 | 200 cc 0.25% bupivacaine at 4.16 cc | 200 cc Saline | 2 3 11 12 | RCT | 6 week |
Reeves 2009 [16] | 31 | 30 | 41 | 69 | 240 cc 0.2% ropivacaine or 0.375% ropivacaine at 5 cc/h | 240 cc Saline | 2 3 6 7 8 11 | RCT | 2 day |
Gomez-Cardero 2011 | 25 | 25 | 38 | 71 | 300 cc 0.2% ropivacaine at a speed of 5 cc/h | 300 cc Saline | 12 | RCT | 1 month |
Zhang 2011 [12] | 27 | 26 | 47.2 | 67 | 199 cc 2 mg/ml ropivacaine plus 2 ml 2 mg/ml ketorolac at 4 cc/h | 199 cc saline | 1 2 3 5 6 7 9 10 11 12 14 | RCT | 3 month |
Goyal 2013 [10] | 75 | 75 | 45.3 | 63 | 300 cc 0.5% bupivacaine | 300 cc Saline | 6 7 8 9 10 11 12 | RCT | 6 week |
Williams 2013 [11] | 26 | 25 | 41.2 | 67 | 0.5% bupivacaine at 2 cc/h | Saline | 2, 3 9 13 9 10 14 | RCT | 1 y |
Ali 2015 [18] | 97 | 95 | 36.5 | 69 | 100 cc 7.5 mg/ml ropivacaine at 2 cc/h | 100 cc Saline | 2 3 4 7 10 11 12 13 | RCT | 3 m |